Publicações

BOLERO-4: Multicenter, Open-Label, Phase Ii Study of Everolimus plus Letrozole as First-Line Therapy in Er+, Her2(-) Metastatic Breast Cancer.

AuthID
P-00P-8Q4

Author(s)

Gradishar, WJ

Bachelot, TD

Saletan, S

Graham, AM

Rubini Liedke, PER

Azevedo, SJ

Sriuranpong, V

Cardoso, F

Document Type

Abstract

Year published

2013

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 31, Issue: 15

Conference

49Th Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: MAY 31-JUN 04, 2013, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol

Indexing

Wos^®

Metadata
Sources

Publication Identifiers

Wos: WOS:000335419605491

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

BOLERO-4: Multicenter, Open-Label, Phase Ii Study of Everolimus plus Letrozole as First-Line Therapy in Er+, Her2(-) Metastatic Breast Cancer.

Useful Links

Get Help

Autenticação Federada (Click on the image)

BOLERO-4: Multicenter, Open-Label, Phase Ii Study of Everolimus plus Letrozole as First-Line Therapy in Er+, Her2(-) Metastatic Breast Cancer.

Useful Links

Get Help